MA25493A1 - Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux. - Google Patents

Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.

Info

Publication number: MA25493A1
Authority: MA; Morocco
Prior art keywords: pyrazole; derivatives; amino; preparation; tumor agents
Prior art date: 1999-08-12

Application number

MA26549A

Other languages

English (en)

Inventor

Paolo Pevarello

Gabriella Traquandi

Mario Varasi

Martha A Warpehoski

Maria Gabriella Brasca

Paolo Orsini

Edward L Fritzen

Betsy S Pierce

Original Assignee

Pharmacia Italia Spa

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-12

Filing date

2002-03-11

Publication date

2002-07-01

2002-03-11 Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa

2002-07-01 Publication of MA25493A1 publication Critical patent/MA25493A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Pulmonology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA26549A 1999-08-12 2002-03-11 Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux. MA25493A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37283199A	1999-08-12	1999-08-12

Publications (1)

Publication Number	Publication Date
MA25493A1 true MA25493A1 (fr)	2002-07-01

Family

ID=23469802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26549A MA25493A1 (fr)	1999-08-12	2002-03-11	Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.

Country Status (35)

Country	Link
US (2)	US7034049B1 (fr)
EP (1)	EP1202733B1 (fr)
JP (1)	JP2003507329A (fr)
KR (1)	KR20020060160A (fr)
CN (1)	CN1373662A (fr)
AP (1)	AP2002002442A0 (fr)
AR (1)	AR026122A1 (fr)
AT (1)	ATE305782T1 (fr)
AU (1)	AU4971400A (fr)
BG (1)	BG106480A (fr)
BR (1)	BR0013143A (fr)
CA (1)	CA2383555C (fr)
CZ (1)	CZ2002422A3 (fr)
DE (1)	DE60023012T2 (fr)
DK (1)	DK1202733T3 (fr)
EA (1)	EA005373B1 (fr)
EE (1)	EE200200065A (fr)
ES (1)	ES2249270T3 (fr)
GE (1)	GEP20053476B (fr)
HK (1)	HK1046866A1 (fr)
HR (1)	HRP20020128A2 (fr)
HU (1)	HUP0203542A3 (fr)
IL (1)	IL147923A0 (fr)
IS (1)	IS6265A (fr)
MA (1)	MA25493A1 (fr)
MX (1)	MXPA02001498A (fr)
NO (1)	NO20020684L (fr)
NZ (1)	NZ517237A (fr)
OA (1)	OA12046A (fr)
PE (1)	PE20010130A1 (fr)
PL (1)	PL353455A1 (fr)
SK (1)	SK1812002A3 (fr)
WO (1)	WO2001012189A1 (fr)
YU (1)	YU9602A (fr)
ZA (1)	ZA200201511B (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901691D0 (en)	1999-01-26	1999-03-17	Cerebrus Ltd	Chemical compounds
HUP0203542A3 (en) *	1999-08-12	2003-07-28	Upjohn Co	3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
AU2972701A (en)	2000-02-07	2001-08-14	Bristol Myers Squibb Co	3-aminopyrazole inhibitors of cyclin dependent kinases
JP2004507455A (ja)	2000-04-25	2004-03-11	ブリストル−マイヤーズ　スクイブ　カンパニー	サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
DE10037310A1 (de) *	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
SK2002003A3 (en) *	2000-08-31	2004-04-06	Pfizer Prod Inc	Pyrazole derivatives and their use as protein kinase inhibitors
US20020103185A1 (en) *	2000-08-31	2002-08-01	Sanner Mark A.	Pyrazole derivatives
NZ525892A (en) *	2000-11-27	2004-11-26	Pharmacia Italia S	Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
US6455559B1 (en) *	2001-07-19	2002-09-24	Pharmacia Italia S.P.A.	Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
NZ527767A (en) *	2001-01-26	2004-11-26	Pharmacia Italia S	Chromane derivatives, process for their preparation and their use as antitumor agents
JP2004526721A (ja) *	2001-03-02	2004-09-02	エフ．ホフマン−ラ　ロシュ　アーゲー	Ｉｐアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体
SE0100902D0 (sv)	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
SE0100903D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
US6787555B2 (en)	2001-04-30	2004-09-07	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en)	2001-04-30	2004-04-27	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
JP2004535411A (ja)	2001-05-25	2004-11-25	ブリストルーマイヤーズスクイブカンパニー	マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
DE10148617A1 (de) *	2001-09-25	2003-04-24	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) *	2001-09-25	2007-05-03	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
ATE440094T1 (de) *	2001-09-27	2009-09-15	Equispharm Co Ltd	Fumagillolderivate und verfahren zu deren herstellung
SE0103710D0 (sv)	2001-11-07	2001-11-07	Astrazeneca Ab	Compounds
US7514406B2 (en) *	2001-11-27	2009-04-07	Fred Hutchinson Cancer Research Center	Methods for inhibiting deacetylase activity
SE0202539D0 (sv)	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
GB0221246D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
US6593477B1 (en)	2002-10-29	2003-07-15	Eastman Kodak Company	Synthesis of 3-acylaminopyrazoles
JP4926403B2 (ja) *	2002-12-10	2012-05-09	ヴァイロケムファーマインコーポレイテッド	フラビウイルス感染の処置もしくは予防のための化合物および方法
UA81790C2 (uk)	2002-12-19	2008-02-11	Фармация Италия С.П.А.	Заміщені піролопіразольні похідні як інгібітори кінази
AU2003294376A1 (en) *	2003-01-06	2004-08-10	Eli Lilly And Company	Heteroaryl compounds
PL378117A1 (pl) *	2003-02-11	2006-03-06	Prosidion Limited	Tricyklopodstawione związki amidowe
CA2519899A1 (fr) *	2003-03-27	2004-10-14	Merck & Co., Inc.	Compositions ophtalmiques pour traiter une hypertension oculaire
SE0301446D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
EA010904B1 (ru)	2003-05-22	2008-12-30	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2005009344A2 (fr)	2003-06-05	2005-02-03	Elan Pharmaceuticals, Inc.	Amino acide amidyle pyrazoles acyles et composes relatifs
US7141568B2 (en)	2003-07-09	2006-11-28	Pfizer Italia S.R.L.	Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005023761A2 (fr)	2003-09-11	2005-03-17	Kemia, Inc.	Inhibiteurs des cytokines
CA2552558A1 (fr) *	2004-01-16	2005-08-11	Wyeth	Inhibiteurs a base de sulfonamides heterocycliques de la production des beta-amyloides contenant un azole
WO2005072731A1 (fr) *	2004-01-29	2005-08-11	X-Ceptor Therapeutics, Inc.	Derives de 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide et composes apparentes utiles comme modulateurs des recepteurs lies a l'oestrogene dans le traitement du cancer, de l'arthrite rhumatoide ou de troubles neurologiques
ES2631362T3 (es)	2004-01-30	2017-08-30	Vertex Pharmaceuticals Incorporated	Moduladores de transportadores de casete de unión a ATP
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
TW200526204A (en)	2004-02-03	2005-08-16	Pharmacia Italia Spa	1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (fr) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	Inhibiteur des kinases et utilisation de cet inhibiteur
US7648992B2 (en)	2004-07-05	2010-01-19	Astrazeneca Ab	Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) *	2004-07-05	2004-07-05	Astrazeneca Ab	Novel compounds
JP2008521864A (ja)	2004-12-03	2008-06-26	トランステック・ファーマ、インコーポレイテッド	ヘテロ芳香族グルコキナーゼ活性化剤
SE0403086D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Compounds
SE0403085D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Novel componds
US7361672B2 (en)	2004-12-23	2008-04-22	Hoffmann-La Roche Inc.	Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) *	2005-01-13	2008-07-11	Aventis Pharma Sa	Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2008007113A2 (fr) *	2006-07-14	2008-01-17	Astex Therapeutics Limited	Combinaisons pharmaceutiques
KR100965040B1 (ko)	2005-07-11	2010-06-21	미쓰비시 타나베 파마 코퍼레이션	옥심 유도체 및 그의 제조 방법
WO2007009898A1 (fr)	2005-07-19	2007-01-25	Nerviano Medical Sciences S.R.L.	Composes 1h-thieno[2,3-c]pyrazole servant d'inhibiteurs de kinase
KR20080090381A (ko) *	2005-08-29	2008-10-08	제라드 엠. 하우지	테라뮤틴 조절물질
TW200736227A (en)	2005-12-23	2007-10-01	Astrazeneca Ab	New compounds III
WO2007081966A2 (fr) *	2006-01-09	2007-07-19	University Of Southern California	Petites molécules pour traiter un cancer et des troubles de prolifération cellulaire anormale
WO2007095383A2 (fr) *	2006-02-15	2007-08-23	Myriad Genetics, Inc.	Promédicaments
UY30183A1 (es) *	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
US8211925B2 (en) *	2006-04-28	2012-07-03	Transtech Pharma, Inc.	Benzamide glucokinase activators
US20090118336A1 (en) *	2006-05-03	2009-05-07	Laurent David	Pyrazole derivatives and their use as pi3k inhibitors
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
TW200831488A (en) *	2006-11-29	2008-08-01	Astrazeneca Ab	Novel compounds
US7737149B2 (en) *	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008084873A1 (fr) *	2007-01-10	2008-07-17	Mitsubishi Tanabe Pharma Corporation	Dérivé oxime
EP2105435A4 (fr) *	2007-01-10	2011-06-15	Mitsubishi Tanabe Pharma Corp	Dérivé d'hydrazone
CN101622231B (zh) *	2007-02-28	2013-12-04	艾德维纳斯医疗私人有限公司	作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
KR100923540B1 (ko) *	2007-11-23	2009-10-27	한국과학기술연구원	5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
MX2010014234A (es) *	2008-06-19	2011-03-25	Astrazeneca Ab	Compuestos pirazol 436.
KR101696936B1 (ko)	2008-07-10	2017-01-16	잇반샤단호우징 화루마바레프로제쿠토 시엥기코우	퀴놀린카르복사미드 유도체를 유효 성분으로 하는 ｓｔａｔ３ 저해제
US20110129467A1 (en)	2008-07-24	2011-06-02	Nerviano Medical Sciences S.R.L.	Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US8557983B2 (en)	2008-12-04	2013-10-15	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en)	2008-12-04	2010-06-24	Abbott Laboratories	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2376480B1 (fr) *	2008-12-05	2016-06-01	AbbVie Inc.	Agents induisant l'apoptose sélectifs pour bcl-2 pour le traitement du cancer et des maladies immunes
US8563735B2 (en)	2008-12-05	2013-10-22	Abbvie Inc.	Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en)	2008-12-05	2013-11-19	Abbvie Inc.	BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
UA106740C2 (uk) *	2009-01-30	2014-10-10	Глаксосмітклайн Ллс	Кристалічний гідрохлорид n-{(1s)-2-аміно-1-[(3-фторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1h-піразол-5-іл)-2-тіофенкарбоксаміду
WO2010129681A1 (fr) *	2009-05-05	2010-11-11	Van Andel Research Institute	Méthodes de traitement de troubles liés à l'autophagie
KR20120059558A (ko) *	2009-08-19	2012-06-08	암비트 바이오사이언시즈 코포레이션	바이아릴 화합물 및 이의 사용 방법
EP2491030B1 (fr) *	2009-10-22	2015-07-15	Fibrotech Therapeutics PTY LTD	Analogues à cycles condensés d'agents anti-fibrotiques
JP2013510092A (ja) *	2009-11-05	2013-03-21	レクシコンファーマシューティカルズインコーポレイテッド	がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤
CN110269856A (zh)	2010-03-30	2019-09-24	维颂公司	多取代芳族化合物作为凝血酶的抑制剂
WO2011156321A1 (fr)	2010-06-07	2011-12-15	Novomedix, Llc	Composés furanyliques et leur utilisation
JP2013530180A (ja)	2010-06-16	2013-07-25	パーデュー、ファーマ、リミテッド、パートナーシップ	アリール置換インドールおよびその使用
BR112013010320B8 (pt) *	2010-11-03	2022-10-11	Dow Agrosciences Llc	Composições pesticidas.
EP2651930B1 (fr) *	2010-12-16	2015-10-28	Boehringer Ingelheim International GmbH	Inhibiteurs biarylamide de production de leukotriènes
RU2652638C2 (ru)	2010-12-17	2018-04-28	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
FR2978441A1 (fr) *	2011-07-25	2013-02-01	Diverchim	Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
AR087701A1 (es) *	2011-08-31	2014-04-09	Japan Tobacco Inc	Derivados de pirazol con actividad inhibidora de sglt1
US9056867B2 (en) *	2011-09-16	2015-06-16	Novartis Ag	N-substituted heterocyclyl carboxamides
AU2013252946A1 (en)	2012-04-27	2014-12-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
EP2775843B1 (fr)	2011-10-26	2021-09-01	Dow AgroSciences LLC	Compositions pesticides et procédés associés
US9282739B2 (en)	2012-04-27	2016-03-15	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US9708288B2 (en)	2012-04-27	2017-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US20140179712A1 (en)	2012-12-21	2014-06-26	Astrazeneca Ab	Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) *	2013-01-18	2016-04-06	北京大学	E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
KR20150130405A (ko)	2013-03-15	2015-11-23	베르선 코포레이션	트롬빈의 억제제로서의 할로게노피라졸
AR095308A1 (es)	2013-03-15	2015-10-07	Glaxosmithkline Ip Dev Ltd	Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
RU2678830C2 (ru)	2013-03-15	2019-02-04	Версеон Корпорейшн	Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
SMT201700152T1 (it)	2013-03-15	2017-05-08	Glaxosmithkline Ip Dev Ltd	Derivati piridinici come inibitori della chinasi riarrangiata durante la trasfezione (ret)
EP2996689A1 (fr) *	2013-04-17	2016-03-23	Albert-Ludwigs-Universität Freiburg	Composés destinés à être utilisés comme inhibiteurs de bromodomaine
CN103265535B (zh) *	2013-05-14	2015-06-17	浙江医药高等专科学校	抗肿瘤化合物、其制备方法和用途
MX2016002626A (es) *	2013-08-30	2016-06-06	Ambit Biosciences Corp	Compuestos de biarilacetamida y metodos de uso de los mismos.
CA2925952A1 (fr)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Procedes de preparation de composes pesticides
EP3057429A4 (fr)	2013-10-17	2017-08-09	Dow AgroSciences LLC	Procédés de préparation de de composés pesticides
CA2925914A1 (fr)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Procedes de preparation de composes pesticides
KR20160074540A (ko)	2013-10-17	2016-06-28	다우 아그로사이언시즈 엘엘씨	살충성 화합물의 제조 방법
WO2015058028A1 (fr)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Procédés de préparation de composés pesticides
KR20160075565A (ko)	2013-10-17	2016-06-29	다우 아그로사이언시즈 엘엘씨	살충성 화합물의 제조 방법
CA2925953C (fr)	2013-10-17	2021-11-02	Dow Agrosciences Llc	Procedes de preparation de composes pesticides
US9474276B2 (en)	2013-10-22	2016-10-25	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
RU2016119569A (ru)	2013-10-22	2017-11-28	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Синергетические пестицидные композиции и относящиеся к ним способы
TW201519775A (zh)	2013-10-22	2015-06-01	Dow Agrosciences Llc	協同性殺蟲組成物及相關方法（七）
AU2014340422B2 (en)	2013-10-22	2017-06-29	Corteva Agriscience Llc	Pesticidal compositions and related methods
AU2014340416B2 (en)	2013-10-22	2017-09-07	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
US9295260B2 (en)	2013-10-22	2016-03-29	Dow Agrosciences Llc	Pesticidal compositions and related methods
EP3060055A4 (fr)	2013-10-22	2017-03-29	Dow AgroSciences LLC	Compositions pesticides synergiques et méthodes associées
KR20160074628A (ko)	2013-10-22	2016-06-28	다우 아그로사이언시즈 엘엘씨	상승작용적 살충 조성물 및 관련 방법
RU2667777C2 (ru)	2013-10-22	2018-09-24	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Пестицидные композиции и связанные с ними способы
TW201519780A (zh)	2013-10-22	2015-06-01	Dow Agrosciences Llc	殺蟲組成物及相關方法（二）
CN105792651A (zh)	2013-10-22	2016-07-20	美国陶氏益农公司	杀虫组合物和与其相关的方法
WO2015061142A1 (fr)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Compositions pesticides synergiques et procédés associés
US9491944B2 (en)	2013-10-22	2016-11-15	Dow Agrosciences Llc	Pesticidal compositions and related methods
US9788546B2 (en)	2013-10-22	2017-10-17	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
KR20160074634A (ko)	2013-10-22	2016-06-28	다우 아그로사이언시즈 엘엘씨	상승작용적 살충 조성물 및 관련 방법
WO2015061146A1 (fr)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Compositions pesticides synergiques et procédés associés
RU2016119560A (ru)	2013-10-22	2017-11-28	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Синергетические пестицидные композиции и относящиеся к ним способы
WO2015143653A1 (fr)	2014-03-26	2015-10-01	Merck Sharp & Dohme Corp.	Inhibiteurs de la kinase trka, compositions et méthodes associées
US9029556B1 (en)	2014-07-31	2015-05-12	Dow Argosciences Llc	Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112017000565A2 (pt)	2014-07-31	2017-11-07	Dow Agrosciences Llc	processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
BR112017000293A2 (pt)	2014-07-31	2017-10-31	Dow Agrosciences Llc	processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
CA2958058A1 (fr)	2014-08-19	2016-02-25	Dow Agrosciences Llc	Procede de preparation de 3-(3-chloro-1h-pyrazol-1-yl)pyridine
CR20170093A (es)	2014-09-10	2017-07-17	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos como inhibidores de ret (reorganizado durante la transfección)
ES2819871T3 (es)	2014-09-10	2021-04-19	Glaxosmithkline Ip Dev Ltd	Compuestos utilizados como inhibidores de la quinasa reordenada durante la transfección (RET)
CA2960985A1 (fr)	2014-09-12	2016-03-17	Dow Agrosciences Llc	Procede de preparation de 3-(3-chloro-1h-pyrazol-1-yl)pyridine
JP2017528486A (ja)	2014-09-17	2017-09-28	ヴァーセオンコーポレイション	セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
GB201416513D0 (en) *	2014-09-18	2014-11-05	Astex Therapeutics Ltd And Cancer Res Technology Ltd	Pharmaceutical compounds
HK1246164A1 (zh)	2015-02-27	2018-09-07	Verseon Corporation	作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CA2978170C (fr)	2015-03-09	2024-02-27	Aurigene Discovery Technologies Limited	Derives de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilises en tant qu'inhibiteurs de cdk
EP3291813A4 (fr)	2015-05-06	2019-01-02	The Regents of The University of California	Modulateurs de k-ras
MY198769A (en)	2015-06-04	2023-09-25	Aurigene Oncology Ltd	Substituted heterocyclic derivatives as cdk inhibitors
CN110023310B (zh)	2016-08-12	2024-05-10	阿西纳斯公司	用于调节激酶级联的联芳组合物和方法
WO2018125817A1 (fr)	2016-12-29	2018-07-05	Dow Agrosciences Llc	Procédés de préparation de composés pesticides
EP3562818B1 (fr) *	2016-12-29	2022-05-18	ENYO Pharma	Dérivés de thiophène en tant qu'antiviraux
BR112019008372B1 (pt)	2016-12-29	2021-11-09	Dow Agrosciences Llc	Processo para preparação de compostos pesticidas
CA3052036A1 (fr)	2017-02-03	2018-08-09	Certa Therapeutics Pty Ltd.	Composes anti-fibrotiques
MA49014A (fr) *	2017-03-21	2020-02-05	Arbutus Biopharma Corp	Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
TW201900638A (zh) *	2017-04-20	2019-01-01	加州大學董事會	Ｋ－ｒａｓ調節劑
US11040945B2 (en)	2017-12-06	2021-06-22	Lin Bioscience Pty Ltd.	Tubulin inhibitors
EP3746422A4 (fr) *	2018-02-01	2021-06-09	The University Of Sydney	Composés anticancéreux
EP3774768A4 (fr) *	2018-04-04	2022-01-05	Aurigene Discovery Technologies Limited	Dérivés de pyrazole substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13
TW202043205A (zh)	2018-12-31	2020-12-01	美商拜歐米富士恩有限公司	Menin-mll相互作用之抑制劑
MX2021007925A (es)	2018-12-31	2021-10-26	Biomea Fusion Llc	Inhibidores irreversibles de la interaccion menina-mll.
IL295177A (en) *	2020-01-29	2022-09-01	Foghorn Therapeutics Inc	compounds and their uses
CN111793034B (zh) *	2020-07-24	2021-11-19	华中科技大学	苯并咪唑盐衍生物与制备抗肿瘤药物的应用
JP2023545588A (ja) *	2020-10-16	2023-10-30	ツェーエムエム－フォルシュングスツェントルムフュアモレクラレメディツィンゲーエムベーハー	ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
TW202229268A (zh) *	2020-12-22	2022-08-01	大陸商上海拓界生物醫藥科技有限公司	Ｃｄｋ２抑制劑及其製備方法
CA3228627A1 (fr)	2021-08-11	2023-02-16	Thomas Butler	Inhibiteurs covalents de l'interaction menine-mll pour le diabete sucre
CN119816500A (zh)	2021-08-20	2025-04-11	拜欧米富士恩公司	用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
IL313539A (en) *	2021-12-10	2024-08-01	Prothena Biosciences Ltd	Methods for treating neurological disorders
WO2023203172A1 (fr) *	2022-04-20	2023-10-26	Proxygen Gmbh	Composés d'ubiquitine ligase cullin ring hétérocycliques et leurs utilisations
WO2024155719A1 (fr)	2023-01-18	2024-07-25	Biomea Fusion, Inc.	Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll
CN116496151B (zh) *	2023-04-26	2024-08-23	长沙医学院	一种利用Catellani策略制备芴酮衍生物的方法
CN118221668A (zh) *	2024-03-19	2024-06-21	华南农业大学	一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162360A (en)	1991-06-24	1992-11-10	Warner-Lambert Company	2-heteroatom containing urea and thiourea ACAT inhibitors
WO1996014843A2 (fr)	1994-11-10	1996-05-23	Cor Therapeutics, Inc.	Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases
AU5135998A (en)	1996-12-03	1998-06-29	Banyu Pharmaceutical Co., Ltd.	Novel urea derivatives
CA2288787A1 (fr)	1997-05-22	1998-11-26	G.D. Searle And Co.	Derives de pyrazole comme inhibiteurs de kinase p38
EP1041982B1 (fr)	1997-12-22	2011-10-19	Bayer HealthCare LLC	Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees
TR200002617T2 (tr) *	1997-12-22	2000-11-21	Bayer Corporation	Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
HUP0203542A3 (en) *	1999-08-12	2003-07-28	Upjohn Co	3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
US6455559B1 (en) *	2001-07-19	2002-09-24	Pharmacia Italia S.P.A.	Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

2000
- 2000-05-05 HU HU0203542A patent/HUP0203542A3/hu unknown
- 2000-05-05 JP JP2001516535A patent/JP2003507329A/ja not_active Withdrawn
- 2000-05-05 HK HK02108532.6A patent/HK1046866A1/zh unknown
- 2000-05-05 AP APAP/P/2002/002442A patent/AP2002002442A0/en unknown
- 2000-05-05 GE GE4758A patent/GEP20053476B/en unknown
- 2000-05-05 DK DK00931906T patent/DK1202733T3/da active
- 2000-05-05 EA EA200200248A patent/EA005373B1/ru not_active IP Right Cessation
- 2000-05-05 HR HR20020128A patent/HRP20020128A2/hr not_active Application Discontinuation
- 2000-05-05 CN CN00812732A patent/CN1373662A/zh active Pending
- 2000-05-05 KR KR1020027001857A patent/KR20020060160A/ko not_active Withdrawn
- 2000-05-05 CZ CZ2002422A patent/CZ2002422A3/cs unknown
- 2000-05-05 IL IL14792300A patent/IL147923A0/xx unknown
- 2000-05-05 BR BR0013143-1A patent/BR0013143A/pt not_active Application Discontinuation
- 2000-05-05 WO PCT/US2000/006699 patent/WO2001012189A1/fr not_active Ceased
- 2000-05-05 ES ES00931906T patent/ES2249270T3/es not_active Expired - Lifetime
- 2000-05-05 SK SK181-2002A patent/SK1812002A3/sk unknown
- 2000-05-05 AT AT00931906T patent/ATE305782T1/de not_active IP Right Cessation
- 2000-05-05 EE EEP200200065A patent/EE200200065A/xx unknown
- 2000-05-05 OA OA1200200051A patent/OA12046A/en unknown
- 2000-05-05 CA CA002383555A patent/CA2383555C/fr not_active Expired - Fee Related
- 2000-05-05 YU YU9602A patent/YU9602A/sh unknown
- 2000-05-05 MX MXPA02001498A patent/MXPA02001498A/es active IP Right Grant
- 2000-05-05 EP EP00931906A patent/EP1202733B1/fr not_active Expired - Lifetime
- 2000-05-05 AU AU49714/00A patent/AU4971400A/en not_active Abandoned
- 2000-05-05 DE DE60023012T patent/DE60023012T2/de not_active Expired - Fee Related
- 2000-05-05 US US10/048,486 patent/US7034049B1/en not_active Expired - Fee Related
- 2000-05-05 NZ NZ517237A patent/NZ517237A/xx unknown
- 2000-05-05 PL PL00353455A patent/PL353455A1/xx not_active Application Discontinuation
- 2000-05-15 PE PE2000000453A patent/PE20010130A1/es not_active Application Discontinuation
- 2000-05-16 AR ARP000102347A patent/AR026122A1/es unknown
- 2000-09-22 US US09/667,603 patent/US6218418B1/en not_active Expired - Fee Related
2002
- 2002-02-11 IS IS6265A patent/IS6265A/is unknown
- 2002-02-11 NO NO20020684A patent/NO20020684L/no not_active Application Discontinuation
- 2002-02-22 ZA ZA200201511A patent/ZA200201511B/xx unknown
- 2002-03-05 BG BG06480A patent/BG106480A/xx unknown
- 2002-03-11 MA MA26549A patent/MA25493A1/fr unknown

Also Published As

Publication number	Publication date
AP2002002442A0 (en)	2002-03-31
EP1202733B1 (fr)	2005-10-05
CZ2002422A3 (cs)	2002-11-13
SK1812002A3 (en)	2003-02-04
EP1202733A4 (fr)	2003-05-14
HK1046866A1 (zh)	2003-01-30
DK1202733T3 (da)	2005-10-31
BR0013143A (pt)	2002-06-11
EA005373B1 (ru)	2005-02-24
BG106480A (en)	2002-09-30
AU4971400A (en)	2001-03-13
EP1202733A1 (fr)	2002-05-08
CN1373662A (zh)	2002-10-09
OA12046A (en)	2006-05-02
DE60023012T2 (de)	2006-07-20
ZA200201511B (en)	2003-05-28
KR20020060160A (ko)	2002-07-16
PL353455A1 (en)	2003-11-17
AR026122A1 (es)	2003-01-29
DE60023012D1 (de)	2006-02-16
NZ517237A (en)	2004-02-27
PE20010130A1 (es)	2001-02-01
GEP20053476B (en)	2005-03-25
WO2001012189A8 (fr)	2001-08-02
HUP0203542A3 (en)	2003-07-28
ATE305782T1 (de)	2005-10-15
US7034049B1 (en)	2006-04-25
CA2383555C (fr)	2009-02-17
IL147923A0 (en)	2002-08-14
IS6265A (is)	2002-02-11
US6218418B1 (en)	2001-04-17
EA200200248A1 (ru)	2002-08-29
YU9602A (sh)	2004-11-25
JP2003507329A (ja)	2003-02-25
NO20020684D0 (no)	2002-02-11
HUP0203542A2 (en)	2003-05-28
CA2383555A1 (fr)	2001-02-22
NO20020684L (no)	2002-04-03
WO2001012189A1 (fr)	2001-02-22
EE200200065A (et)	2003-04-15
MXPA02001498A (es)	2003-07-21
HRP20020128A2 (en)	2003-04-30
ES2249270T3 (es)	2006-04-01

Publication	Publication Date	Title
MA25493A1 (fr)	2002-07-01	Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
MA25433A1 (fr)	2002-04-01	Derives d'arylmethyl-carbonylamino-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux
MA25223A1 (fr)	2001-07-02	Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26471A1 (fr)	2004-12-20	Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2457A1 (fr)	2004-11-08	Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
MA26468A1 (fr)	2004-12-20	Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA23831A1 (fr)	1996-10-01	Derives de quinazoline, procede pour leur preparation et composition les contenant
FR2786768B1 (fr)	2004-10-15	Derives d'acide 2-amino-bicyclo(3.1.o) hexane-2,6- dicarboxylique et procede pour leur preparation
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26499A1 (fr)	2004-12-20	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA24158A1 (fr)	1997-12-31	Derives d'imidazole substitues, procede pour leur preparation et compositions les contenant
FR2740132B1 (fr)	1997-12-19	Procede pour la preparation de 1,1,1,3,3-pentafluoropropane
MA21983A1 (fr)	1991-07-01	Procede pour la preparation de derives de quinolone .
MA26519A1 (fr)	2004-12-20	Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2791059B1 (fr)	2005-04-01	Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee
MA24182A1 (fr)	1997-12-31	Procede pour la preparation de 2,4-diaminopyrimidines substituees
MA26642A1 (fr)	2004-12-20	Derives de sulfonylbenzene nouveaux, procédé pour leur preparation et compositions pharmaceutiques les contenant.
DZ2912A1 (fr)	2004-03-01	Procédé pour la préparation de pyrazolo Ä4,3-DÜpyrimidine-7-ones, et intermédiaires pour ce procédé.
MA26552A1 (fr)	2004-12-20	Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26609A1 (fr)	2004-12-20	Derives de retiferol, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
EP1023250A4 (fr)	2001-03-21	Procede de preparation de 2,6-dialkylnaphtalene